Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy
Abstract
Triple-negative breast cancer (BCa) (TNBC) is a deadly form of human BCa with limited treatment options and poor prognosis. In our prior analysis of over 2200 breast cancer samples, the G protein-coupled receptor CCR5 was expressed in > 95% of TNBC samples. A humanized monoclonal antibody to CCR5 (leronlimab), used in the treatment of HIV-infected patients, has shown minimal side effects in large patient populations.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 23, 2021
- Source ID
- 10.1186/s13058-021-01391-1
Entities
People
- Anthony W Ashton
- David W. Speicher
- Dong Ni
- Hsin-Yao Tang
- Min Wang
- Richard G Pestell
- Xuanmao Jiao
- Zhao Zhang
- Zhiping Li
Organizations
- National Cancer Institute
- United States Department of Defense